Catcher Technology (2474) Q2 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2024 earnings summary
31 Mar, 2026Executive summary
Revenue in 2Q24 was NT$4.672bn, up 27.7% quarter-over-quarter but down 32.2% year-over-year due to a high base in 2Q23 from shipment recovery.
Net profit after tax (NPAT) for 2Q24 was NT$3.435bn, down 24.9% quarter-over-quarter and 23.4% year-over-year.
For 1H24, revenue totaled NT$8.331bn, down 20.1% year-over-year; NPAT was NT$8.011bn, up 49.3% year-over-year.
Total comprehensive income for 1H24 reached NT$12.70bn, up 80% year-over-year.
Basic EPS for 2Q24 was NT$5.05, compared to NT$6.73 in 1Q24 and NT$6.59 in 2Q23; 1H24 EPS was NT$11.77, up from NT$7.75 in 1H23.
Financial highlights
Gross profit for 2Q24 reached NT$1.59bn, up 56.0% quarter-over-quarter and down 30.0% year-over-year; gross margin improved to 34.0%.
Operating profit for 2Q24 was NT$953mn, down 30% year-over-year.
Non-operating income for 2Q24 was NT$3.60bn, mainly from interest and FX gains.
EBITDA for 2Q24 was NT$1.426bn, up from NT$880mn in 1Q24 but down from NT$2.082bn in 2Q23.
FX gains contributed NT$978mn in 2Q24 and NT$3,886mn in 1H24.
Outlook and guidance
Revenue growth in 2Q24 was driven by promotions from brand customers, but the year-over-year decline reflects a high base effect from last year.
Management continues to monitor economic conditions and aims for stable and growing dividends.
The company is focused on sustainable operations and long-term development.
Latest events from Catcher Technology
- Net profit jumped 44% to NT$13.20bn on stable revenue, margin gains, and high dividends.2474
Q4 202431 Mar 2026 - Q3 2024 revenue and margins rose, but net profit and cash fell amid FX losses and capital returns.2474
Q3 202431 Mar 2026 - Gross margin reached 35% as revenue grew 18.9% year-over-year, but net profit fell sharply.2474
Q1 202531 Mar 2026 - 2Q25 revenue increased, but FX losses and margin pressure led to a net loss; diversification continues.2474
Q2 202531 Mar 2026 - 3Q25 net profit more than doubled year-over-year despite a 5% revenue decline.2474
Q3 202531 Mar 2026 - 4Q25 revenue fell, but gross margin rose; 2025 profit and EPS dropped despite medtech growth.2474
Q4 202531 Mar 2026